Showing 751-760 of 836 results for "".
- Allergan Aesthetics and BOTOX Cosmetic Reveal New 'See Yourself' Campaign Casthttps://modernaesthetics.com/news/allergan-aesthetics-and-botox-cosmetic-reveal-new-see-yourself-campaign-cast/2473299/Allergan Aesthetics is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX Cosmetic 'See Yourself' campaign. After receiving nearly 20,000 submissions t
- Revision Skincare, RVL Pharmaceuticals Form Partnershiphttps://modernaesthetics.com/news/revision-skincare-rvl-pharmaceuticals-form-partnership/2473288/Revision Skincare® is partnering with RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, to collaborate on a variety of marketing efforts within the medical aesthetics industry, working together to address significant unmet consumer needs. Revisions says that, with shared
- Survey Seeks Input on Price Transparency and Surprise Medical Billshttps://modernaesthetics.com/news/survey-seeks-input-on-price-transparency-and-surprise-medical-bills/2473283/To better understand healthcare providers’ views on price transparency, surprise medical bills, and the No Surprises Act a new survey is being fielded. Results of the brief, 4-minute, online survey will be publis
- Coming Soon: An Increased Demand for Plus-Sized Body Contouring Procedureshttps://modernaesthetics.com/news/coming-soon-an-increased-demand-for-plus-sized-body-contouring-procedures/2473266/Plus size models have gained in popularity in the fashion business and on social media, and plastic surgeons will likely see an increased demand for procedures that enhance the plus size body type, according to researchers from Boston University School of Medicine (BUSM).
- FDA Nod for Sientra’s Low Plus Profile Projection Breast Implanthttps://modernaesthetics.com/news/fda-nod-for-sientras-low-plus-profile-projection-breast-implant-1/2473263/The U.S. Food and Drug Administration (FDA) approved Sientra’s Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for board-certi
- Cynosure Rolls Out PicoSure Pro Devicehttps://modernaesthetics.com/news/cynosure-rolls-out-picosure-pro-device/2473248/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. The FDA-cleared 755nm picosecond laser on the market, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide
- Rion Aesthetics Initiates Series Ahttps://modernaesthetics.com/news/rion-aesthetics-initiates-series-a/2473241/With the initiation of Series A funding, Rion Aesthetics presents a unique investment opportunity for aesthetic providers. Rion plans on closing the Series A in the second quarter of 2022. Rion, a regenerati
- Endymed's US Subsidiary Taps Bill Scott as New Presidenthttps://modernaesthetics.com/news/endymeds-us-subsidiary-taps-bill-scott-as-new-president/2473215/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Aquavit's Neurotoxin Submitted to FDAhttps://modernaesthetics.com/news/aquavits-neurotoxin-submitted-to-fda/2473213/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Cynosure and Jeisys Medical Japan Expand Partnershiphttps://modernaesthetics.com/news/cynosure-and-jeisys-medical-japan-expand-partnership/2473209/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&